FDA Approves Camizestrant for Advanced Breast Cancer Driven by ESR1 Mutations

Patients with advanced hormone-driven breast cancer who develop resistance to their initial treatments now have a targeted oral therapy available to suppress their tumors. On September 4, 2026, the Food and Drug Administration granted accelerated approval to camizestrant, a next-generation estrogen receptor degrader, for use alongside standard CDK4/6 inhibitors in patients whose cancer carries an ESR1 mutation.[1][8]

The approval fundamentally changes how oncologists manage HR-positive, HER2-negative breast cancer—the most common subtype of the disease. Historically, these tumors are treated with drugs that block estrogen, which the cancer relies on as fuel. However, the cancer frequently adapts. In up to 40% of advanced cases, the tumor eventually mutates its estrogen receptor gene, known as ESR1.[2][3]

This specific mutation allows the cancer to grow even when estrogen is successfully blocked by first-line therapies. Once the ESR1 mutation develops, standard endocrine treatments lose their efficacy, and the disease typically begins to progress again. For years, this resistance point marked a difficult transition in a patient's treatment journey, often signaling the exhaustion of hormone-based options.[3][6]

Camizestrant addresses this resistance directly through a different mechanical approach. Rather than merely attempting to block the mutated receptor, the drug binds to it and triggers its complete degradation. By dismantling the mutated engine driving the tumor's growth, the therapy removes the cancer's primary survival mechanism.[4][7]

The FDA approved the drug to be used in combination with a CDK4/6 inhibitor, a class of medications that interrupts the cell division cycle. By deploying both drugs simultaneously, oncologists can shut down the estrogen receptor pathway while simultaneously blocking the cancer cells from replicating, creating a dual blockade that is significantly harder for the tumor to bypass.[3][8]

For patients, accessing the new therapy does not require an invasive tissue biopsy to confirm the mutation. The FDA tied the approval to the use of a companion diagnostic blood test that detects circulating tumor DNA (ctDNA). This liquid biopsy approach allows doctors to identify the ESR1 mutation from fragments of tumor DNA shed into the bloodstream.[1][5]

This diagnostic capability translates to a more proactive treatment strategy. Oncologists can monitor a patient's blood during their initial treatment regimen; if the ESR1 mutation appears in the bloodstream, they can pivot to the camizestrant combination before the physical tumors show significant growth on a radiological scan, staying one step ahead of the disease.[2][5]

The agency's accelerated approval is based on progression-free survival data from mid-stage clinical trials, which demonstrated that patients receiving the camizestrant combination experienced a statistically significant delay in tumor growth compared to those on older endocrine therapies. The FDA's approval documents did not include direct statements from agency officials, but the regulatory filings noted the drug's capacity to address this specific resistance pathway. Because the approval was granted under the accelerated pathway, the manufacturer is legally required to provide further data from ongoing Phase 3 trials to confirm the drug's long-term impact on overall survival.[1][6]

In the immediate term, the decision provides a crucial bridge for patients facing disease progression. By effectively targeting the ESR1 mutation, camizestrant allows patients to remain on manageable oral medications, preserving their quality of life and significantly delaying the physical and logistical toll of transitioning to intravenous chemotherapy.[4][7]